Edward Greeno is an Oncology physician affiliated with University of Minnesota. OpenAlex indexes 58 publications with 1,767 citations (h-index 22); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
909 Fulton St SE
Minneapolis, MN 554554800
Telephone
612-625-3600Provider last certified this registry record 18 Jan 2024.
Clinical trials
- IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Sponsor: Masonic Cancer Center, University of Minnesota
- Chemoradiation in Locally Advanced Pancreatic Cancer
Sponsor: Masonic Cancer Center, University of Minnesota
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
32.6%Serotonin-3 Receptor Antagonist11.2%Ondansetron Hcl100%Part D≥23 patientsAntidiarrheal microorganisms7.1%Creon100%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
24.4%Kinase inhibitor19.1%Imatinib Mesylate51%Sorafenib19%Gleevec16%Lenvima15%Part D<11 patientsNucleoside Analog Antiviral5.3%Lonsurf100%Part D<11 patientsNervous system
18.8%Phenothiazine8.9%Prochlorperazine Maleate100%Part D≥23 patientsOpioid Agonist3.6%Oxycodone Hcl100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1993–1993 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review
JNCI Journal of the National Cancer Institute
2024 - Provider perspective: The clinical value of a novel digital medicine program in gastrointestinal oncology.
Journal of Clinical Oncology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”